Heparin, klotho, and FGF23: the 3-beat waltz of the discordant heart

Marta Martinez-Calle, Valentin David*

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

2 Scopus citations

Abstract

Excess fibroblast growth factor (FGF) 23 signaling in patients with chronic kidney disease induces left ventricular hypertrophy. In this issue, Yanucil et al. investigated the interaction of soluble klotho and heparin with FGF23 and FGF receptor isoforms. They concluded that heparin promotes the FGF23–FGF receptor isoform 4 interaction and FGF23 pathogenic effects, supporting an important role of heparin in the pathogenesis of FGF23-mediated left ventricular hypertrophy in chronic kidney disease.

Original languageEnglish (US)
Pages (from-to)228-230
Number of pages3
JournalKidney international
Volume102
Issue number2
DOIs
StatePublished - Aug 2022

Funding

VD received research funding from Akebia Therapeutics and Vifor Pharma and consulting honoraria from Keryx Biopharmaceuticals, Vifor Pharma, Luitpold, and Amgen (outside the submitted work). The other author declared no competing interests. VD was supported by grants from the National Institutes of Health (grant nos. R01DK102815 and R01DK114158).

ASJC Scopus subject areas

  • Nephrology

Fingerprint

Dive into the research topics of 'Heparin, klotho, and FGF23: the 3-beat waltz of the discordant heart'. Together they form a unique fingerprint.

Cite this